Press Releases MediciNova, Inc.

Equities

MNOV

US58468P2065

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-02 pm EDT			5-day change	1st Jan Change
1.38 ^USD	+6.98%		+4.55%	-8.00%

Mar. 27	MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 for the Treatment of Macular Injury in Japan	CI
Mar. 12	Medicinova Announces New Data and Results of Mn-166 in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting	Apr. 03	AQ
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)	Apr. 02	GL
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 for the Treatment of Macular Injury in Japan	Mar. 27	AQ
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan	Mar. 26	GL
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society	Mar. 20	GL
MediciNova : Corporate Presentation – March 15, 2024	Mar. 15	PU
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology	Mar. 12	GL
MNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers – February 29, 2024	Feb. 28	PU
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 for the Treatment of Macular Injury in China	Jan. 18	AQ
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China	Jan. 17	GL
MediciNova Announces Abstract Regarding MN-166 in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology	Dec. 22	AQ
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology	Dec. 21	GL
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology	Dec. 21	AQ
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 for the Treatment of Progressive MS in Europe	Dec. 07	AQ
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe	Dec. 06	GL
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe	Dec. 06	AQ
MediciNova : Corporate Presentation – November 20, 2023	Nov. 20	PU
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology	Nov. 20	AQ
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology	Nov. 19	GL
MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology	Nov. 19	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases MediciNova, Inc.

Equities

MNOV

US58468P2065

Press Releases

Filters